Literature DB >> 24511444

Treating symptomatic hyperprolactinemia secondary to a long-acting injectable atypical antipsychotic in a patient with bipolar disorder due to an anoxic brain injury.

McLeod F Gwynette1, Nick Evangelidis1.   

Abstract

Entities:  

Year:  2013        PMID： 24511444      PMCID： PMC3907324          DOI： 10.4088/PCC.13l01544

Source DB:  PubMed          Journal:  Prim Care Companion CNS Disord        ISSN： 2155-7780


× No keyword cloud information.
  5 in total

1.  Hyperprolactinaemia caused by antipsychotic drugs.

Authors:  Angelika Wieck; Peter Haddad
Journal:  BMJ       Date:  2002-02-02

2.  Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.

Authors:  Bun-Hee Lee; Yong-Ku Kim; Sun-Hwa Park
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-03-29       Impact factor: 5.067

3.  Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia.

Authors:  Norio Yasui-Furukori; Hanako Furukori; Norio Sugawara; Akira Fujii; Sunao Kaneko
Journal:  J Clin Psychopharmacol       Date:  2010-10       Impact factor: 3.153

4.  Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.

Authors:  Chih-Ken Chen; Yu-Shu Huang; Shao-Chun Ree; Cheng-Cheng Hsiao
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-08-20       Impact factor: 5.067

5.  Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.

Authors:  Joo-Cheol Shim; Jae-Goo K Shin; Deanna L Kelly; Do-Un Jung; Young-Soo Seo; Kwang-Hyeon Liu; Ji-Hong Shon; Robert R Conley
Journal:  Am J Psychiatry       Date:  2007-09       Impact factor: 18.112
  5 in total
  1 in total

Review 1.  Is Adjunct Aripiprazole Effective in Treating Hyperprolactinemia Induced by Psychotropic Medication? A Narrative Review.

Authors:  Frank M C Besag; Michael J Vasey; Iffah Salim
Journal:  CNS Drugs       Date:  2021-04-20       Impact factor: 5.749
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.